Page last updated: 2024-08-24

irinotecan and Hematologic Malignancies

irinotecan has been researched along with Hematologic Malignancies in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; Rossi, DL; Wang, Y; Zalath, MB1
Cardillo, TM; Goldenberg, DM; Govindan, SV; Sharkey, RM1
Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M1
Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ1

Reviews

2 review(s) available for irinotecan and Hematologic Malignancies

ArticleYear
[Clinical activity spectrum of irinotecan].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome

1998
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
    Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms

2001

Other Studies

2 other study(ies) available for irinotecan and Hematologic Malignancies

ArticleYear
IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Hematologic Neoplasms; HLA-DR Antigens; Humans; Immunoconjugates; Immunoglobulin G; Irinotecan; Melanoma; Mice

2018
Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:1

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Sialic Acid Binding Ig-like Lectin 2

2012